Oral Vancomycin Dosing for Clostridioides difficile Infection
For initial episodes of C. difficile infection, use vancomycin 125 mg orally four times daily for 10 days, regardless of disease severity (non-severe or severe). 1, 2, 3, 4, 5
Initial Episode Treatment
Standard Dosing (Non-Severe and Severe CDI)
- Vancomycin 125 mg orally four times daily for 10 days is the recommended dose for both non-severe and severe initial CDI. 1, 2, 3, 4, 5
- The IDSA/SHEA guidelines strongly recommend vancomycin or fidaxomicin over metronidazole for all initial episodes (strong recommendation, high quality evidence). 3, 4
- Non-severe disease is defined as WBC ≤15,000 cells/mL and serum creatinine <1.5 mg/dL; severe disease is WBC ≥15,000 cells/mL or serum creatinine >1.5 mg/dL. 3
Higher Doses Are NOT Beneficial for Routine Severe CDI
- Do not use higher doses (500 mg four times daily) for routine severe CDI—no clinical benefit has been demonstrated. 2, 6, 7, 8
- European guidelines specifically recommend against using higher doses (>125 mg four times daily) for routine severe CDI, as standard 125 mg dosing yields fecal concentrations 500-1000 times the C. difficile MIC. 2
- Multiple studies confirm no difference in cure rates, time to cure, or complication rates between low-dose (≤500 mg daily) and high-dose (>500 mg daily) vancomycin for severe CDI. 6, 7, 8
Fulminant CDI (Life-Threatening Disease)
For fulminant CDI with hypotension/shock, ileus, or megacolon, escalate to vancomycin 500 mg orally four times daily PLUS intravenous metronidazole 500 mg every 8 hours. 3, 4
- If ileus is present, add rectal vancomycin 500 mg in 100 mL normal saline every 6 hours as a retention enema (weak recommendation, low quality evidence). 3
- Consider early surgical consultation—do not wait until the patient is moribund. 3
Recurrent CDI Treatment
First Recurrence
- If metronidazole was used initially, treat with vancomycin 125 mg four times daily for 10 days. 1, 3, 4
- If standard vancomycin was used initially, use a prolonged tapered and pulsed regimen: 125 mg four times daily for 10-14 days, then twice daily for 7 days, then once daily for 7 days, then every 2-3 days for 2-8 weeks. 1, 3
- Alternative: Fidaxomicin 200 mg twice daily for 10 days shows lower recurrence rates (weak recommendation, moderate quality evidence). 1, 2
Multiple Recurrences (≥2 Relapses)
- Use vancomycin 125 mg four times daily for 10 days, followed by either:
- Alternative: Vancomycin 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days (weak recommendation, low quality evidence). 1, 3
- Fecal microbiota transplantation is recommended for patients with multiple recurrences who have failed appropriate antibiotic treatments (strong recommendation, moderate quality evidence). 1
Pediatric Dosing (Less Than 18 Years)
Non-Severe CDI
Severe/Fulminant CDI
- 10 mg/kg/dose (maximum 500 mg) orally four times daily for 10 days. 1, 3, 4
- Consider adding intravenous metronidazole 10 mg/kg/dose (maximum 500 mg) three times daily in severe/fulminant cases (weak recommendation, low quality evidence). 1
FDA-Approved Pediatric Dosing
- The FDA label recommends 40 mg/kg/day in 3 or 4 divided doses for 7-10 days, not to exceed 2 g daily. 5
Critical Management Principles
- Stop the causative antibiotic immediately—this significantly influences recurrence risk (strong recommendation, moderate quality evidence). 3, 4
- Never use antiperistaltic agents or opiates as they worsen outcomes and increase complications. 2, 3, 4
- Parenteral (IV) vancomycin is completely ineffective for C. difficile infection and should never be used. 3, 4, 5
- Treatment response typically requires 3-5 days after starting therapy. 2, 4
- "Test of cure" is not recommended after CDI treatment. 2, 4
Common Pitfalls to Avoid
- Do not routinely use 500 mg four times daily for severe CDI—this causes unnecessary disruption to colonic flora without clinical benefit. 2
- Monitor serum vancomycin concentrations in patients with renal insufficiency, inflammatory bowel disease, or those receiving concomitant aminoglycosides, as systemic absorption can occur. 5
- In patients >65 years of age, monitor renal function during and after treatment to detect vancomycin-induced nephrotoxicity. 5